πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10023654

Anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023642

Anti-PDGFR-beta antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10017580

Humanized anti-Tn-MUC1 antibodies and their conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10010587

IL-2RΞ²-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 anti

Nektar Therapeutics Β· Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10000564

Methods of treating an inflammatory condition or sensitivity to an allergen with anti-IL-3

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9974744

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. Β· Granted Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9968674

Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibo

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963515

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963504

Anti-CXCL13 antibodies and methods of using the same

VACCINEX, INC. Β· Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957324

Anti-FLT-1 antibodies in treating duchenne muscular dystrophy

Regents of the University of Minnesota Β· Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957305

Anti-C. difficile toxin antibodies and associated methods

The Board of Regents of the University of Oklahoma Β· Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951127

Anti-ANGPTL3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951311

Agents and methods to elicit anti-tumor immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951132

Anti-prokineticin receptor (PROKR) antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9937159

Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and an

Lutonix, Inc. Β· Granted Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9925180

Compounds and anti-tumor NQO1 substrates

The Board of Regents of the University of Texas System Β· Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9926369

Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9919056

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9913900

Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914773

Anti-human folate receptor beta antibodies and methods of use

THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES Β· Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9913822

Combination therapy with an anti-hyaluronan agent and therapeutic agent

HALOZYME, INC. Β· Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884009

Plant composition having moisturizing, anti-wrinkle, and anti-allergic efficacies, and pre

INFINITUS (CHINA) COMPANY LTD. Β· Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878984

Anti-cancer compounds

Northwestern University Β· Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878046

Adverse side-effects associated with administration of an anti-hyaluronan agent and method

HALOZYME, INC. Β· Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted